Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul;146(1):222-226.
doi: 10.1016/j.jaci.2020.01.039. Epub 2020 Feb 5.

Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

Annette T Hastie  1 , David T Mauger  2 , Loren C Denlinger  3 , Andrea Coverstone  4 , Mario Castro  4 , Serpil Erzurum  5 , Nijar Jarjour  3 , Bruce D Levy  6 , Deborah A Meyers  7 , Wendy C Moore  8 , Brenda Phillips  2 , Sally E Wenzel  9 , John V Fahy  10 , Elliot Israel  6 , Eugene R Bleecker  7 ; NHLBI SARP 3 Investigators
Collaborators, Affiliations
Clinical Trial

Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

Annette T Hastie et al. J Allergy Clin Immunol. 2020 Jul.

Abstract

Combined elevated sputum eosinophils+neutrophils in asthma associated with lowest lung function, greater healthcare utilization, and longitudinally, further spirometric loss, implicating cell-cell interactions or overlapping inflammatory pathways while increased eosinophils or neutrophils alone show less effect.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Declarations: Dr. Hastie reports grants from NIH, Genentech and GSK during the conduct of the study; Dr. Mauger reports grant support from NIH, AstraZeneca, Boehringer-Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and TEVA; Dr. Denlinger has grants from NIH/NHLBI and has consulted with AstraZeneca and Sanofi-Regeneron during the conduct of the study; the extension of the longitudinal phase of the SARP cohort has also been supported by AstraZeneca, Boehringer-Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and TEVA; Dr. Coverstone has nothing to disclose; Dr. Castro receives University Grant Funding from NIH, American Lung Association, PCORI, Pharmaceutical Grant Funding from AstraZeneca, Chiesi, Novartis, GSK, Sanofi-Aventis; consultant fees for Genentech, Theravance, VIDA, Teva, Sanofi-Aventis, is a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, & Teva, and receives Royalties from Elsevier; Dr. Erzurum reports grants from National Institutes of Health (NIH), during the conduct of the study; and Chair of the ABIM Pulmonary Disease Board; Dr. Jarjour has grants from NIH/NHLBI and has consulted with AstraZeneca and Boehringer Ingelheim, and during the extension of the longitudinal phase of the SARP cohort has also been supported, in part, by AstraZeneca, Boehringer-Ingelheim, Genentech, GSK, Sanofi-Genzyme-Regeneron, and TEVA; Dr. Levy reports grants from NIH during the conduct of the study; other from Nocion Therapeutics, from Entrinsic Health, grants and personal fees from Sanofi, personal fees from Pieris Pharmaceuticals, Novartis, AstraZeneca, Corbus Pharmaceuticals, Gossamer Bio, Metera Pharmaceuticals, and Teva, and grants from Samsung Research America outside the submitted work; Dr. Meyers has nothing to disclose; Dr. Moore reports grants from NIH/NHLBI, grants from AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi-Genzyme-Regeneron, and Teva during the conduct of the study; grants and personal fees from AstraZeneca, and Sanofi Regeneron, grants from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Gossamer, and Cumberland Pharmaceuticals outside the submitted work; Dr. Phillips reports grants from National Institutes of Health, grants from Boehringer-Ingelheim, TEVA, AstraZeneca, GlaxoSmithKline, Sanofi, and Genentech during the conduct of the study; Dr. Wenzel reports grants from NIH and personal fees from AstraZeneca, grants and personal fees from GSK during the conduct of the study; grants and personal fees from Sanofi-Regeneron, grants from Boehringer Ingelheim ,Novartis, and TEVA, and personal fees from Pieris outside the submitted work; Dr. Fahy reports grants from NIH/NHLBI, grants from Boehringer Ingelheim during the conduct of the study; personal fees from Boehringer Ingelheim, Pieris, Arrowhead Pharmaceuticals, and Gossamer outside the submitted work, in addition, Dr. Fahy has a patent US20110123530A1 - “Compositions and methods for treating and diagnosing asthma” issued, a patent WO2014153009A2 -Thiosaccharide mucolytic agents. issued, and a patent WO2017197360 - “CT Mucus Score” - A new scoring system that quantifies airway mucus impaction using CT lung scans; Dr. Israel reports personal fees from AstraZeneca, Biometry, Entrinsic Health Solutions, Equillium, Genentech, GlaxoSmithKline, Merck, Novartis, 4D Pharma, Pneuma Respiratory, Regeneron Pharmaceuticals, Sanofi Genzyme, Sienna Biopharmaceutical, TEVA Specialty Pharmaceuticals, and Vitaeris, Inc; grants from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Merck, Novartis, Sanofi, TEVA and Vifor-Pharma; non-financial support from Circassia, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Merck, TEVA Specialty Pharmaceuticals and Vifor-Pharma; other from Vorso Corp, outside the submitted work; Dr. Bleecker reports other from NIH grant, clinical trials through his employer, Wake Forest School of Medicine and University of Arizona for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Johnson and Johnson (Janssen), Novartis, Regeneron, and Sanofi Genzyme, personal fees also serving as a paid consultant for AztraZeneca, MedImmune, Boehringer Ingelheim, Glaxo Smith Kline, Novartis, Regeneron, and Sanofi Genzyme outside the submitted work.

Figures

Figure 1
Figure 1. (A)
Post-bronchodilator FEV1%predicted (B) Absolute Change in Post-Bronchodilator FEV1%predicted and (C) Exacerbations at baseline and each annual visit for subjects stratified by sputum Eos + Neu differential categories determined at baseline. *High Eos+High Neu vs Low Eos+Low Neu, p<0.05; †High Eos+High Neu vs Low Eos+High Neu, p<0.05; + High Eos+High Neu vs High Eos+Low Neu, p<0.05
Figure 1
Figure 1. (A)
Post-bronchodilator FEV1%predicted (B) Absolute Change in Post-Bronchodilator FEV1%predicted and (C) Exacerbations at baseline and each annual visit for subjects stratified by sputum Eos + Neu differential categories determined at baseline. *High Eos+High Neu vs Low Eos+Low Neu, p<0.05; †High Eos+High Neu vs Low Eos+High Neu, p<0.05; + High Eos+High Neu vs High Eos+Low Neu, p<0.05
See this image and copyright information in PMC

References

    1. Al-Samri MT, Benedetti A, Prefontaine D, Olivenstein R, Lemiere C, Nair P, et al. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol 2010;125:1161–1163. - PubMed
    1. Ducharme ME, Prince P, Hassan N, Nair P, Boulet LP. Expiratory flows and airway inflammation in elderly asthmatic patients. Respir Med. 2011;105:1284–9. - PubMed
    1. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 125:1028–1036. - PMC - PubMed
    1. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. for the Asthma Clinical Research Network of the NHLBI. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612–619. - PMC - PubMed
    1. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2013;133:1557–63. - PMC - PubMed